Coherus BioSciences (CHRS) Conference Call Summary Company Overview - **Company**: Coherus BioSciences - **Event**: Jefferies Global Healthcare Conference - **Date**: June 04, 2025 Key Industry Insights - **Focus Areas**: Coherus Oncology is concentrating on three main areas: - Lactorsi (proprietary PD-1 asset) for nasopharyngeal cancer - CHS-114 (anti-CCR8 cytolytic antibody) - Casdozo ketog (IL-27 antagonist) [4][6][40] Core Product Highlights - **Lactorsi**: - Launched in 2024, it is the only preferred treatment for both first-line and follow-on lines in nasopharyngeal cancer - Expected revenue of $40 to $50 million in 2025 [12][40] - Targets a market of approximately $150 to $200 million annually [11] - Demonstrated a 15% increase in overall demand from the previous quarter [12] - **CHS-114**: - Targets T regulatory cells, aiming to selectively deplete them in tumors to enhance immune response - High expression of CCR8 in various solid tumors, including head and neck, gastric, and colorectal cancers [18][23] - Anticipated data readouts in the first half of 2026 [6][8] - **Casdozo ketog**: - First-in-class IL-27 antagonist showing promise in liver cancer with a 38% overall response rate and a 17% complete response rate [33][36] - Expected to enter a global study comparing it with standard care [35] Financial Overview - **Debt Reduction**: Successfully reduced debt to approximately $38.7 million annually after divesting $800 million worth of assets [7][42] - **Cash Position**: Ended Q1 2025 with $82 million in cash, bolstered by a $250 million increase post-divestiture [42][44] - **Cost Management**: Plans to reduce workforce from 225 to about 50 employees, yielding $25 million in savings [42] Strategic Partnerships and Market Opportunities - **Partnerships**: Actively seeking partners for ex-US licensing of pipeline assets [40][41] - **Market Potential**: Combined market opportunity for pipeline assets exceeds $15 billion [6][40] Additional Insights - **Mechanistic Differentiation**: Lactorsi's unique binding mechanism allows for internalization of the PD-1 receptor, enhancing T cell signaling, particularly in low PD-L1 states [9][10][43] - **Clinical Development**: Robust clinical programs with expected results in 2026, focusing on large indications with multibillion-dollar market potential [43][44] - **Regulatory Engagement**: Positive alignment with the FDA regarding the development approach for CHS-114 and Casdozo ketog [28][41] This summary encapsulates the critical points discussed during the conference call, highlighting the strategic direction, product pipeline, financial health, and market opportunities for Coherus BioSciences.

Coherus BioSciences (CHRS) 2025 Conference May 08, 2025 09:00 AM ET Speaker0 So welcome. Good morning. This is the second day of the Citizens Life Science Conference, and it's my pleasure to introduce the next company, Coherus Biosciences. Here for Coherus is, Denny Lemfier, CEO, and Theresa, Lavelle, chief scientific officer and development officer. New title today. Welcome, guys. Appreciate you coming. So I never know exactly who's in the audience or who's listening to, the webcast, and so would love to, ...